Vesalio Secures Class A Funding

Vesalio Secures Class A Funding

Vesalio Secures Class A Funding - June 02, 2021

Vesalio Initiates FDA IDE Stroke Study

Vesalio Initiates FDA IDE Stroke Study

Vesalio announces another key milestone to support entry into the US neurovascular thrombectomy market. Enrollment has commenced in the Vesalio CLEAR(1) acute ischemic stroke FDA IDE clinical trial utilizing the NeVa(TM) thrombectomy technology platform. With twenty participating stroke treatment... - May 11, 2021

Vesalio Attains Key FDA Clinical Study Milestone

Vesalio Attains Key FDA Clinical Study Milestone

Vesalio announces it has accomplished a key FDA IDE study milestone to support entry into the US neurovascular market. Enrollment in the VITAL(1) clinical trial, assessing the company’s NeVa VS™ technology in the treatment of symptomatic cerebral vasospasm following aneurysmal... - April 28, 2021

Vesalio Receives Peripheral FDA 510k Clearance and Additional CE Approval

Vesalio Receives Peripheral FDA 510k Clearance and Additional CE Approval

Vesalio reports it has obtained an FDA 510k clearance and its 4th CE approval. The FDA 510k indication is for the removal of thrombi in peripheral blood vessels. The new CE approval expands the NeVa™ neuro-thrombectomy portfolio. Vesalio’s Drop Zone(TM) technology, designed to remove... - January 28, 2021

Vesalio Reports 2,500 Patient Milestone

Vesalio Reports 2,500 Patient Milestone

Vesalio reports it has surpassed 2,500 clinical cases with the NeVa™ neuro-thrombectomy platform. Physicians have evaluated the Neva Drop Zone™ technology with enthusiasm as it has shown a unique capability of removing the full spectrum of clot types in large vessel occlusion ischemic... - December 07, 2020

Vesalio Expands Sales Network, Initiates Virtual Physician Training and Announces High First Pass Effect Rate Publication

Vesalio Expands Sales Network, Initiates Virtual Physician Training and Announces High First Pass Effect Rate Publication

Vesalio Expands Sales Network, Initiates Virtual Physician Training and Announces High First Pass Effect Rate Publication - September 16, 2020

Vesalio Obtains Additional CE Approval for New Products, NeVa Clinical Data Published

Vesalio Obtains Additional CE Approval for New Products, NeVa Clinical Data Published

Vesalio announces it has obtained its second CE mark approval spanning multiple new NeVa™ neurothrombectomy product designs and technology. The new generation NeVa devices expand on the Drop Zone™ and Smart Marker™ technologies while also introducing first-to-market features such... - May 22, 2019

Vesalio Secures $5 Million Investment Capital Funding

Vesalio Secures $5 Million Investment Capital Funding

Vesalio announces it has recently raised $5 million in funding. The capital will support the continued global expansion of the NeVa™ Neurothrombectomy System, finance key clinical studies and launch new product introductions. “We are very pleased to secure the additional capital... - May 14, 2019

Vesalio Reports Expansion of International Distributor Network and Stroke Congress Exhibition Presence

Vesalio Reports Expansion of International Distributor Network and Stroke Congress Exhibition Presence

Vesalio announces it has executed multiple exclusive distribution agreements in Europe, Latin America, Asia and the Middle East and now has market coverage in 39 countries for the NeVa™ Neuro-thrombectomy System. Along with the increased market and registration activities, Vesalio is... - April 02, 2019

Vesalio Initiates Full Commercial Launch of NeVa at ESMINT Congress

Vesalio Initiates Full Commercial Launch of NeVa at ESMINT Congress

Vesalio Initiates Full Commercial Launch of NeVa at ESMINT Congress - September 12, 2018

Vesalio Reports Expansion of Commercial Distribution, Additional Published Data on the NeVa™ System for Treating Stroke Patients

Vesalio Reports Expansion of Commercial Distribution, Additional Published Data on the NeVa™ System for Treating Stroke Patients

Vesalio announces it has executed multiple exclusive distribution agreements in Europe and now has market coverage in 25 countries for the NeVa Neurothrombectomy System. All channel partners have been trained on the unique features of the NeVa platform and technique that is optimized for capturing... - June 18, 2018

Vesalio Reports Positive Results in Early NeVa™ Human Thrombectomy Procedures and Recently Published Pre-Clinical Data

Vesalio Reports Positive Results in Early NeVa™ Human Thrombectomy Procedures and Recently Published Pre-Clinical Data

Vesalio announces it has completed European enrollment of the first twenty-five human cases in a post-market registry of the proprietary NeVa™ neurothrombectomy platform for the treatment of stroke. With procedures performed at six centers in four countries to date, early results demonstrate... - March 22, 2018

Vesalio Announces NeVa™ Stroke Treatment Product CE Mark Certification

Vesalio Announces NeVa™ Stroke Treatment Product CE Mark Certification

Vesalio announces the CE Mark certification of its first product line, the proprietary NeVa™ neurothrombectomy platform for the treatment of strokes. Developed by a team of physicians that treat stroke, the NeVa mechanical thrombectomy technology was designed to improve “first... - October 31, 2017

Press Releases 1 - 13 of 13